US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

42.55

-1.2700-2.90%

Volume:347.87K

Turnover:14.91M

Market Cap:2.44B

PE:23.75

High:44.44

Open:44.00

Low:42.35

Close:43.82

52wk High:79.18

52wk Low:35.30

Shares:57.44M

Float Shares:38.70M

Volume Ratio:0.54

T/O Rate:0.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.79

EPS(LYR):1.77

ROE:29.74%

ROA:9.38%

PB:6.42

PE(LYR):24.04

Loading ...

Overview Company News Filings

Oddity Tech LTD options imply 15.1% move in share price post-earnings

Oddity Tech Launches METHODIQ Telehealth Platform

Press Release: Immatics Announces Third Quarter 2025 Financial Results and Business Update

ODDITY Tech Ltd. Shareholders Approve Proposals at Annual Meeting

Oddity Tech Ltd. Held Annual General Meeting of Shareholders

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 2025's Top Stocks Priced Below Estimated Value

Simply Wall St.

Press Release: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oddity Tech (ODD) Valuation: Is a 38% Upside Possible After Recent Volatility?

Simply Wall St.

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

Oddity Tech Ltd. to Release Third Quarter 2025 Financial Results

Quoin Pharmaceuticals announces FDA granted ODD to QRX003

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

J.P. Morgan Sticks to Its Buy Rating for ODDITY Tech Ltd. Class A (ODD)

5 Tech Stocks Climbing Benzinga's Value Rankings

Benzinga_recent_news

Press Release: Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ODD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":42.55,"timestamp":1765827712874,"preClose":43.82,"halted":0,"volume":347865,"delay":0,"floatShares":38696732,"shares":57438900,"eps":1.791771,"marketStatus":"Trading","change":-1.27,"latestTime":"12-15 14:42:16 EST","open":44,"high":44.44,"low":42.353,"amount":14905180.374,"amplitude":0.047627,"askPrice":42.65,"askSize":20,"bidPrice":42.55,"bidSize":250,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":43.82,"preHourTrading":{"tag":"盘前","latestPrice":44.15,"preClose":43.82,"latestTime":"08:56 EST","volume":19,"amount":848.4400599999999,"timestamp":1765806964143},"postHourTrading":{"tag":"盘后","latestPrice":43.3394,"preClose":43.82,"latestTime":"19:36 EST","volume":12480,"amount":546944.8837,"timestamp":1765586188778},"volumeRatio":0.544029,"impliedVol":0.5656,"impliedVolPercentile":0.3},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38696732,"roa":"9.38%","roe":"29.74%","lyrEps":1.769608,"volumeRatio":0.544029,"shares":57438900,"dividePrice":0,"high":44.44,"amplitude":0.047627,"preClose":43.82,"low":42.353,"week52Low":35.3,"pbRate":"6.42","psRate":"3.13","week52High":79.1804,"institutionHeld":0,"latestPrice":42.55,"committee":0.851852,"eps":1.791771,"divideRate":0,"volume":347865,"delay":0,"ttmEps":1.791771,"open":44,"prevYearClose":42.02,"prevWeekClose":43.82,"prevMonthClose":43.26,"prevQuarterClose":62.3,"fiveDayClose":42.97,"twentyDayClose":38.73,"sixtyDayClose":62.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-19","symbol":"ODD","fiscalQuarterEnding":"2025/09","expectedEps":0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-08-04","symbol":"ODD","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754280000000,"reportTimeType":"post","actualEps":0.76},{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06},{"market":"US","date":"2024-11-06","symbol":"ODD","fiscalQuarterEnding":"2024/09","expectedEps":0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.5455,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1758690000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2025-12-12","current":23.747454,"percent":0.092749,"low":19.077969,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"high":144.174884,"avg":33.880653,"sd":15.752864,"marketCap":2552583516},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-08-01","current":36.786958,"twenty":24.983991,"median":31.719535,"eighty":41.803173,"marketCap":3911888350},{"date":"2025-08-08","current":29.269388,"twenty":24.988656,"median":31.680004,"eighty":41.755726,"marketCap":3223525522},{"date":"2025-08-15","current":29.576073,"twenty":25.039696,"median":31.613107,"eighty":41.668069,"marketCap":3257301638},{"date":"2025-08-22","current":30.491058,"twenty":25.068568,"median":31.584654,"eighty":40.714949,"marketCap":3358071703},{"date":"2025-08-29","current":30.947283,"twenty":25.079845,"median":31.470545,"eighty":40.692965,"marketCap":3408317165},{"date":"2025-09-05","current":31.494754,"twenty":25.083205,"median":31.459553,"eighty":40.65779,"marketCap":3468611719},{"date":"2025-09-12","current":31.935772,"twenty":25.085195,"median":31.488146,"eighty":40.645966,"marketCap":3517182333},{"date":"2025-09-19","current":31.793835,"twenty":25.089994,"median":31.584179,"eighty":40.616226,"marketCap":3501550411},{"date":"2025-09-26","current":29.994279,"twenty":25.105422,"median":31.49222,"eighty":40.594895,"marketCap":3303359978},{"date":"2025-10-03","current":30.739447,"twenty":25.114201,"median":31.481537,"eighty":40.590201,"marketCap":3385427566},{"date":"2025-10-10","current":26.927161,"twenty":25.127573,"median":31.451808,"eighty":40.571566,"marketCap":2965569012},{"date":"2025-10-17","current":26.01968,"twenty":25.135101,"median":31.389658,"eighty":40.56278,"marketCap":2865625373},{"date":"2025-10-24","current":24.575011,"twenty":25.135101,"median":31.29655,"eighty":40.533764,"marketCap":2706519695},{"date":"2025-10-31","current":22.697464,"twenty":25.089994,"median":31.260978,"eighty":40.483338,"marketCap":2499739752},{"date":"2025-11-07","current":20.840778,"twenty":25.062794,"median":31.168388,"eighty":40.3235,"marketCap":2295257365},{"date":"2025-11-14","current":21.127625,"twenty":24.961585,"median":31.125566,"eighty":40.286255,"marketCap":2326848745},{"date":"2025-11-21","current":20.632506,"twenty":24.914074,"median":31.026394,"eighty":40.195833,"marketCap":2272856204},{"date":"2025-11-28","current":22.556538,"twenty":24.864441,"median":30.973992,"eighty":40.067661,"marketCap":2484805645},{"date":"2025-12-05","current":23.453377,"twenty":24.800183,"median":30.947283,"eighty":39.942199,"marketCap":2583600507},{"date":"2025-12-12","current":23.171811,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"marketCap":2552583516}],"updateTime":1765827736242},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584920776","title":"Oddity Tech LTD options imply 15.1% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920776?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:50","pubTimestamp":1763578210,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Oddity (ODD) Tech LTD is 1.5x normal with calls leading puts 8:3. Implied volatility suggests the market is anticipa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oddity-tech-ltd-options-imply-15-1-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oddity-tech-ltd-options-imply-15-1-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","ODD","BK4183"],"gpt_icon":0},{"id":"2584806953","title":"Oddity Tech Launches METHODIQ Telehealth Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2584806953","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584806953?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:00","pubTimestamp":1763474434,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. has announced the launch of METHODIQ, a new telehealth platform designed to deliver customized, high-efficacy dermatology treatments through online diagnosis. METHODIQ initially focuses on conditions such as acne, hyperpigmentation, and eczema, with plans to expand into additional medical areas. The platform utilizes advanced AI-driven analysis and a suite of 28 core products with over 100 personalized treatment plans, including prescription, OTC, and cosmetic formulations. This move leverages Oddity's direct-to-consumer model and technology expertise to enter the medical care market, following four years of investment and testing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL7s9cps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2584640789","title":"Press Release: Immatics Announces Third Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584640789","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584640789?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:00","pubTimestamp":1763380800,"startTime":"0","endTime":"0","summary":"randomized, controlled Phase 3 trial, SUPRAME, in previously treated. advanced melanoma ongoing; interim and final analyses will occur in 2026. -- Anzu-cel  PRAME Cell Therapy: One-time infusion continues to show. strong clinical benefit and favorable tolerability in 16 patients with. metastatic uveal melanoma in latest update on Phase 1b data presented at. the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months,mPFS of 8.5 months and mOS not reached at 14.3 months mFU. -- IMA203CD8 PRAME Cell Therapy : Phase 1a clinical trial ongoing with. next data update, including dose escalation data in ovarian cancer,melanoma and synovial sarcoma, planned to be presented at ESMO. -- TCR Bispecifics: IMA402 and IMA401 TCR Bispecifics achieved clinical. and durable responses in heavily pre-treated, last-line patients with a. -- TCR Bispecifics data support development opportunities for IMA402 PRAME. Bispecific in cutaneous melanoma, gynecologic cancers and in combination. with IMA401","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","BK4139","IMTX","ORR","PFS","ODD","OS","BK4195","BK4211","BK4097"],"gpt_icon":0},{"id":"2583468236","title":"ODDITY Tech Ltd. Shareholders Approve Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583468236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583468236?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:31","pubTimestamp":1763155882,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) just unveiled an announcement. On November 13, 2025, ODDITY Tech Ltd. held its Annual General Meeting of Shareh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-ltd-shareholders-approve-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-ltd-shareholders-approve-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","ODD","BK4183"],"gpt_icon":0},{"id":"2583023681","title":"Oddity Tech Ltd. Held Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2583023681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583023681?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:09","pubTimestamp":1763154550,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. held its Annual General Meeting of Shareholders on November 13, 2025. At the meeting, shareholders voted on all proposals set forth in the company's notice and proxy statement, with each proposal receiving approval by the required majority.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1tTpyR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2582722793","title":"Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2582722793","media":"GlobeNewswire","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582722793?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955100,"startTime":"0","endTime":"0","summary":"- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO - - Rare disease commercia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186298/0/en/Immix-Biopharma-Appoints-Chief-Commercial-Officer-to-Drive-NXC-201-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","IE0009354923.USD","BK4183","BK4023","BK4595","BK4596","STRK","ODD","NXC","BK4588","BK4585","BK4516"],"gpt_icon":1},{"id":"2582862650","title":"Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862650","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582862650?lang=en_us&edition=fundamental","pubTime":"2025-11-09 06:13","pubTimestamp":1762639980,"startTime":"0","endTime":"0","summary":"Deep, stable and durable reductions in kallikrein observedAmong 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184092/0/en/Intellia-Therapeutics-Presents-Positive-Pooled-Phase-1-2-Data-of-Lonvoguran-Ziclumeran-lonvo-z-in-Patients-with-Hereditary-Angioedema.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","LU1169590202.USD","BK4535","ODD","IE0009354923.USD","HAE","BK4611","LU0205194284.USD","BK4556","LU1169589451.USD","LU1861558580.USD","LU1861559042.SGD","BK4183","IE0034390439.USD","IE00BLDYK493.USD","LU0012050646.USD","IE00B19Z6F94.USD","BK4198","LU0205193047.USD","NTLA","IE00B64QTZ34.USD","LU0106261612.USD","CRSP"],"gpt_icon":0},{"id":"2581804238","title":"November 2025's Top Stocks Priced Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2581804238","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581804238?lang=en_us&edition=fundamental","pubTime":"2025-11-08 01:08","pubTimestamp":1762535291,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a challenging landscape with tech stocks under pressure and major indices experiencing significant losses, investors are keenly observing economic indicators like labor market data and Federal Reserve interest rate decisions. In this environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for growth amidst broader market volatility.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/november-2025s-top-stocks-priced-below-estimated-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/november-2025s-top-stocks-priced-below-estimated-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LGND","BK4150","LU2237443895.HKD","LU0234570918.USD","LU0203347892.USD","CPAY","MNY","LU0545039389.USD","ABBV","LU0985320562.USD","BK4104","LU1839511570.USD","LU0234572021.USD","LU1989772923.USD","SEDG","SG9999011175.SGD","LU0708994859.HKD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU2237443382.USD","IE0004445239.USD","LU2237443622.USD","HBAN","BK4588","GENI","CAI","LU1496350502.SGD","SGHC","LU0256863811.USD","BUSE","LU2237443549.SGD","CAI.AU","IE0002141913.USD","INSP","LU2237443978.SGD","LU1983299246.USD","ODD","LU0861579265.USD","IE00BDGV0183.EUR","LU1496350171.SGD","IE00BVYPNV92.GBP","LU1934455863.HKD","LU0823414478.USD","LU1003077747.HKD","LU0912757837.SGD","LU0965509010.AUD","SG9999015986.USD","BK4077","ONB"],"gpt_icon":0},{"id":"2580737096","title":"Press Release: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737096","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737096?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:00","pubTimestamp":1762264800,"startTime":"0","endTime":"0","summary":"-- Data update from vopimetostat  showed 2L MTAP-del pancreatic cancer median progression free survival  7.2 months--. -- Combination studies with RAS inhibitors ongoing, data anticipated 2026 --. -- 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity --. -- $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 --. BOSTON, Nov. 04, 2025  -- Tango Therapeutics, Inc. , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights.-- In October 2025, vopimetostat clinical data were announced in a corporate. presentation. With a mPFS of 7.2 months, the data support the planned. pivotal study in 2L MTAP-del pancreatic cancer anticipated to start in. -- There is robust enrollment ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2298322129.HKD","ODD","IE00BZ199S13.USD","BK4512","LU2357305700.SGD","IE00BFXG0V08.USD","LU0724618433.USD","LU1721428933.USD","BK4139","BK4548","LU1720051017.SGD","LU1861215975.USD","LU1720051108.HKD","LU0347712357.USD","LU2413666699.HKD","MTD","LU1093756168.USD","LU1548497426.USD","LU1093756325.SGD","SITC","LU1978683503.SGD","BK4585","LU1854103824.USD","BK4231","IE0009354923.USD","IE00BD6J9T35.USD","LU2413666426.HKD","BK4080","LU0124384867.USD","BK4539","BK4567","BK4588","TNGX","BK4533","LU2211817866.USD","BK4183","BK4121","LU1861214812.USD","BK4141","BK4007","ON","BK4605","IE00BFMHRM44.USD","LU1854104046.USD","IE00BYQQ9H92.USD","LU0348723411.USD","LU1861220033.SGD","LU2360107325.USD","LU1861219969.SGD"],"gpt_icon":0},{"id":"2580279992","title":"Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580279992","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580279992?lang=en_us&edition=fundamental","pubTime":"2025-11-04 09:50","pubTimestamp":1762221000,"startTime":"0","endTime":"0","summary":"NANJING, China, Nov. 4, 2025 /PRNewswire/ -- LeadsBiolabs  today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the 67th Annual Meeting of the American Society of Hematology , taking place December 6 to 9, 2025, in Orlando, Florida. These include one oral presentation, three poster presentations, and one online publication.LBL-034: Multiple Studies Featured, Clinical Data Highlighted in Oral Presentation. Session:First oral presentation of the first session on the opening day. Title:Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T-cell engager with an affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model. LBL-076: A Strong Debut and International Recognition for Preclinical Innovation. LBL-076 is a first-in-class trispecific T-cell engager designed to simultaneously target CD38, GPRC5D, and CD3.I","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/oral-presentation-five-hematologic-malignancies-studies-by-leads-biolabs-to-be-featured-at-ash-2025-302603343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH.AU","BK7057","BK4183","IE0009354923.USD","BK4109","ASH","LU2463526074.USD","ODD"],"gpt_icon":0},{"id":"2580721625","title":"Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580721625","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580721625?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:45","pubTimestamp":1762177500,"startTime":"0","endTime":"0","summary":"- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov.  03, 2025  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179312/0/en/Immix-Biopharma-s-NXC-201-NEXICART-2-Clinical-Trial-Results-Selected-for-Oral-Presentation-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AL","BK4572","BK4109","IE00B19Z6F94.USD","IE0034390439.USD","BK4022","LU2463526074.USD","NXC","LU1169590202.USD","CAR","BK4183","LU1169589451.USD","BK4104","BK4230","ODD","IE0009354923.USD","ASH"],"gpt_icon":0},{"id":"2580421278","title":"Oddity Tech (ODD) Valuation: Is a 38% Upside Possible After Recent Volatility?","url":"https://stock-news.laohu8.com/highlight/detail?id=2580421278","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580421278?lang=en_us&edition=fundamental","pubTime":"2025-11-01 16:59","pubTimestamp":1761987596,"startTime":"0","endTime":"0","summary":"Oddity Tech (ODD) shares have been on a bit of a ride lately, trading at $45.25 as of the last close and showing a nearly 19% gain over the past year. Despite some ups and downs this month, the company’s annual revenue growth of 16% hints at evolving investor sentiment toward its prospects.\nSee our latest analysis for Oddity Tech.\nOddity Tech’s 1-year total shareholder return of nearly 19% stands out, especially considering a sharp pullback in the last month with a 26% share price decline...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-valuation-is-a-38-upside-possible-after-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-valuation-is-a-38-upside-possible-after-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"2578648062","title":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648062","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648062?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:30","pubTimestamp":1761564600,"startTime":"0","endTime":"0","summary":"Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct.  27, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","ODD","BK4535","BK4556","BK4588","BK4183","CRSP","ATTR","BK4585","LU1861559042.SGD","BK4139","IE0009354923.USD","BK4611","LU1861558580.USD"],"gpt_icon":0},{"id":"2577597889","title":"Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2577597889","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577597889?lang=en_us&edition=fundamental","pubTime":"2025-10-24 18:12","pubTimestamp":1761300720,"startTime":"0","endTime":"0","summary":"BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. andRibocure Pharmaceuticals AB ,today announcedthat the European Medicines Agency  has granted Orphan Drug Designation  to RBD1016 for the treatment of Hepatitis D Virus  infection.About Hepatitis D Virus HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus . HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available.Despite its severity, HDV remains underdiagnosed and underserved. The development of targeted therapies like RBD1016 offers a promising path forward for patients and clinicians seeking more effective and durable treatment options.Suzhou Ribo Life Science Co. Ltd. is a pioneer in advancing RNAi technology and industrializ","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-granted-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-for-hepatitis-delta-virus-hdv-infection-302593816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4588","ODD","BK4183","IE0009354923.USD","BK4081","BK4585","HDV"],"gpt_icon":0},{"id":"2577769319","title":"Oddity Tech Ltd. to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577769319","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577769319?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:30","pubTimestamp":1761165036,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. will announce its third quarter 2025 financial results on November 19, 2025, after market close. The results will be released on the Investors section of ODDITY's website at Investors section of ODDITY's website. A conference call to discuss the results will be held on November 20, 2025, at 8:30 a.m. Eastern Time, and a webcast will be accessible on the same webpage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via GlobeNewswire  on October 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLKW2rv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","BK4585","IE00BKPKM429.USD","LU2095319765.USD","ODD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2577878199","title":"Quoin Pharmaceuticals announces FDA granted ODD to QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2577878199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577878199?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:35","pubTimestamp":1761050122,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to its lead product can...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-granted-odd-to-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-granted-odd-to-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4183","BK4139","QNRX","ODD"],"gpt_icon":0},{"id":"2576072851","title":"Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2576072851","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576072851?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961600,"startTime":"0","endTime":"0","summary":"Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169315/0/en/Radiopharm-Theranostics-Provides-Positive-Clinical-Updates-Across-Four-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","BK4128","BK4139","DSMC","SOC","ODD","RADX","RAD","BK4213"],"gpt_icon":0},{"id":"2576034812","title":"J.P. Morgan Sticks to Its Buy Rating for ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576034812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576034812?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:16","pubTimestamp":1760699767,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Cory Carpenter reiterated a Buy rating on ODDITY Tech Ltd. Class A today and set a price target of $82.00. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2575758508","title":"5 Tech Stocks Climbing Benzinga's Value Rankings","url":"https://stock-news.laohu8.com/highlight/detail?id=2575758508","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575758508?lang=en_us&edition=fundamental","pubTime":"2025-10-16 02:04","pubTimestamp":1760551440,"startTime":"0","endTime":"0","summary":"Tracking upward trends in value rankings can help investors uncover opportunities before they gain broader attention. Over the past week, Benzinga's system highlighted five technology stocks showing sharp improvements in value scores.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/15/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/15/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/25/10/48234235/5-tech-stocks-climbing-benzingas-value-rankings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/25/10/48234235/5-tech-stocks-climbing-benzingas-value-rankings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4535","SQQQ","CLMB","USAW.SI","BK4106","TQQQ","TSYW.SI","PSQ","IE0009354923.USD","QID","BK4226","PAY",".IXIC","MNQmain","IE00B7SZL793.SGD","BK4539","NVIW.SI","PENG","IE00B19Z4B17.USD","BK4183","IE0031619046.USD","BK4140","ODD","NQmain","BK4227","USJW.SI","IE00B66KJ199.SGD","QLD","TASK","BK4141"],"gpt_icon":1},{"id":"2575893027","title":"Press Release: Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2575893027","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575893027?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:30","pubTimestamp":1760527800,"startTime":"0","endTime":"0","summary":"HAIFA, Israel, Oct. 15, 2025  -- Minovia Therapeutics Ltd. , a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome , a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track Designation in MDS, as well as both Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome.\"We continue to receive validation from the FDA for the potential of our lead product, MNV-201, this time in the form of Orphan Drug Designation in MDS. MNV-201 targets the mitochondria, a critical multi-functional organelle. FDA designations such as ODD underscore the urgency of drugs treating these diseases affecting smaller populations, while providing additional benefits across th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4190","MAT","ODD","BK4539","LPAA","IE0009354923.USD","BK4183","BK4139","LENZ","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":114,"code":"91000000","status":"200"}]}}